MedTrace Logo

Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer

NCT00136487 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2009-12-09

No results posted yet for this study

Summary

The purpose of this study is to learn the effects (both good and bad) that celecoxib has on prostate cancer and patients with prostate cancer. This study is looking at what effects celecoxib has on prostate specific antigen (PSA) level. PSA is a marker specific to prostate cancer. An increase or decrease in this level in the blood can indicate if a patient's prostate cancer is getting worse or better.

Conditions

Interventions

DRUG

Celecoxib

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Beth Israel Deaconess Medical Center

    collaborator OTHER

  • Emerson Hospital, Concord, MA

    collaborator OTHER

  • Brigham and Women's Hospital

    collaborator OTHER

  • Hartford Hospital

    collaborator OTHER

  • Lowell General Hospital

    collaborator OTHER

  • Massachusetts General Hospital

    collaborator OTHER

  • M.D. Anderson Cancer Center

    collaborator OTHER

  • University of Michigan Rogel Cancer Center

    collaborator OTHER

  • Dana-Farber Cancer Institute

    lead OTHER

Principal Investigators

  • Philip W. Kantoff, MD · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31
Primary Completion
2006-09-30
Completion
2006-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00136487 on ClinicalTrials.gov